112 related articles for article (PubMed ID: 32231715)
1. The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis.
Zhao Z; Li L; Wang Z; Duan J; Bai H; Wang J
J Cancer; 2020; 11(11):3106-3113. PubMed ID: 32231715
[No Abstract] [Full Text] [Related]
2. The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non-small cell lung cancer: A meta-analysis.
Guo L; Zhou G; Huang M; Tang K; Xu J; Chen J
Clin Respir J; 2024 Apr; 18(4):e13748. PubMed ID: 38584122
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis.
Yi XF; Song J; Gao RL; Sun L; Wu ZX; Zhang SL; Huang LT; Ma JT; Han CB
Front Oncol; 2022; 12():863666. PubMed ID: 35785185
[TBL] [Abstract][Full Text] [Related]
4. Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation.
Yoshimura A; Yamada T; Okura N; Takeda T; Hirose K; Kubota Y; Shiotsu S; Hiranuma O; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30875919
[TBL] [Abstract][Full Text] [Related]
5. EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients.
Zheng Q; Hong S; Huang Y; Zhao H; Yang Y; Hou X; Zhao Y; Ma Y; Zhou T; Zhang Y; Fang W; Zhang L
Clin Transl Med; 2020 Feb; 9(1):17. PubMed ID: 32067121
[TBL] [Abstract][Full Text] [Related]
6.
Buder A; Hochmair MJ; Setinek U; Pirker R; Filipits M
Transl Lung Cancer Res; 2020 Apr; 9(2):239-245. PubMed ID: 32420063
[TBL] [Abstract][Full Text] [Related]
7. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor T790M mutation as a prognostic factor in EGFR-mutant non-small cell lung cancer patients that acquired resistance to EGFR tyrosine kinase inhibitors.
Ma G; Zhang J; Jiang H; Zhang N; Yin L; Li W; Zhou Q
Oncotarget; 2017 Nov; 8(59):99429-99437. PubMed ID: 29245913
[TBL] [Abstract][Full Text] [Related]
9. Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer.
Fernandes MGO; Sousa C; Jacob M; Almeida L; Santos V; Araújo D; Novais Bastos H; Magalhães A; Cirnes L; Moura CS; Queiroga H; Cruz-Martins N; Hespanhol V
Front Oncol; 2021; 11():602924. PubMed ID: 34026599
[No Abstract] [Full Text] [Related]
10. Impact of
Igawa S; Ono T; Kasajima M; Ishihara M; Hiyoshi Y; Kusuhara S; Nishinarita N; Fukui T; Kubota M; Sasaki J; Hisashi M; Yokoba M; Katagiri M; Naoki K
Cancer Manag Res; 2019; 11():4883-4892. PubMed ID: 31213907
[No Abstract] [Full Text] [Related]
11. Curative effectiveness and safety of osimertinib in the treatment for non-small-cell lung cancer: a meta-analysis of the experimental evidence.
Chen P; Chen F; Lei J; Zhou B
Onco Targets Ther; 2018; 11():9033-9047. PubMed ID: 30588016
[TBL] [Abstract][Full Text] [Related]
12. Patients with advanced non-small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real-world data analysis.
Chang N; Duan J; Wang L; Dong Z; Liu Z
Oncol Lett; 2020 Sep; 20(3):2266-2272. PubMed ID: 32782544
[TBL] [Abstract][Full Text] [Related]
13. Risk factors of acquired T790M mutation in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer.
Ouyang W; Yu J; Huang Z; Chen G; Liu Y; Liao Z; Zeng W; Zhang J; Xie C
J Cancer; 2020; 11(8):2060-2067. PubMed ID: 32127933
[No Abstract] [Full Text] [Related]
14. Patterns and Treatment Strategies of Osimertinib Resistance in T790M-Positive Non-Small Cell Lung Cancer: A Pooled Analysis.
Wang C; Zhao K; Hu S; Li M; Song Y
Front Oncol; 2021; 11():600844. PubMed ID: 33763349
[TBL] [Abstract][Full Text] [Related]
15. Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example.
Wei B; Zhao C; Li J; Zhao J; Ren P; Yang K; Yan C; Sun R; Ma J; Guo Y
Mol Oncol; 2019 May; 13(5):1226-1234. PubMed ID: 30927306
[TBL] [Abstract][Full Text] [Related]
16. Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program.
Santos ES; Kaplan B; Kirshner E; Croft EF; Sequist LV; Chau M; Munley J; Oxnard GR
Oncol Ther; 2018 Jun; 6(1):45-58. PubMed ID: 32700141
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Osimertinib.
Park JY; Jang SH; Lee CY; Kim T; Chung SJ; Lee YJ; Kim HI; Kim JH; Park S; Hwang YI; Jung KS
Tuberc Respir Dis (Seoul); 2022 Apr; 85(2):155-164. PubMed ID: 35045686
[TBL] [Abstract][Full Text] [Related]
18. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of resistance to osimertinib.
Lazzari C; Gregorc V; Karachaliou N; Rosell R; Santarpia M
J Thorac Dis; 2020 May; 12(5):2851-2858. PubMed ID: 32642198
[TBL] [Abstract][Full Text] [Related]
20. L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib.
Callegari D; Ranaghan KE; Woods CJ; Minari R; Tiseo M; Mor M; Mulholland AJ; Lodola A
Chem Sci; 2018 Mar; 9(10):2740-2749. PubMed ID: 29732058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
